

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>				ATTY DOCKET NO.	SERIAL NO.		
				5670-01-MJA	10/075, 929		
				APPLICANT(S)			
				LESLIE MAGNUS-MILLER AND DOUGLAS A. SALT			
				FILING DATE	GROUP		
				2-13-02	AU 1615		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JL		5,352,638	10/04/1994	Beall et al.	510	10	
JL	↑	5,321,012	06/14/1994	Mayer et al.	514	25	
JL	↓	5,556,838	09/17/1996	Mayer et al.	514	25	
JL		5,234,929	08/10/1993	Chelen	514	269	
JL		5,420,270	05/30/1995	Chandrakumar et al.	540	488	
JL							
JL							
JL							
JL							
JL							
FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
JL	9607412A1	03/14/1996	WO			✓	NO
JL	8905642A	06/29/1989	WO			✓	NO
JL	8701036A	02/26/1987	WO			✓	NO
JL	9807447	02/26/1998	WO			✓	NO
JL	2255279A	11/04/1992	GB			✓	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
JL			PCT International Search Report PCT/US98/17083				
JL			KATHRYN J. ELLIOT, "New Analgesics Emerge From Pain Pathogenesis Research", Oncology News International, April 1997, pp 14-15				
EXAMINER				DATE CONSIDERED			
JAMES M. SPEAR				05-20-2003			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No. EJ676053605USS
PD-5670-01-MJA

EXAMINER James M. Spear

DATE CONSIDERED

05-20-2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No. EJ676053605US
PD-5670-01-MJA

EXAMINER JAMES M. SPEAR

DATE CONSIDERED

ERED 05-20-2003

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional) 5670-01-M...	Application Number 10/075,929
Applicant(s) LESLIE MAGNUS-MILLER AND DOUGLAS A. SALTEL	
Filing Date 02-13-02	Group Art Unit AU 1615

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
<i>js</i>	ALAN Z. SEGAL, et al., "Gabapentin as a Novel Treatment for Postherpetic Neuralgia", Neurology, Vol. 46, April 1996, pp 1175-1176
<i>↑</i>	MEGUMI SHIMOMYAMA, et al., "Gabapentine Enhances the Anticonvulsive Effects of Spinal Morphine in the Rat Tail-flick Test", Pain, Vol. 72, 1997, pp 375-382
	RONALD J. TALLARIDA, et al., "Statistical Analysis of Drug-Drug and Site-Site Interactions with Isobolograms, Life Sciences, Vol. 45, 1989, pp 947-961
	RONALD J. TALLARIDA, "Statistical Analysis of Drug Combinations for Synergism", Pain, Vol. 49, 1992, pp 93-97
<i>↓</i>	RONALD J. TALLARIDA et al., "Testing for Synergism Over a Range of Fixed Ratio Drug Combinations: Replacing the Isobogram", Life Sciences, Vol. 58, No. 2, 1996, pp 23-28
<i>js</i>	JOHN J. ZAPP, "Postpoliomyelitis Pain Treated with Gabapentin", American Family Physician, Vol. 53, No. 8, June 1996, pp 2442-2445

EXAMINER JAMES M. SPEAR	DATE CONSIDERED 05-20-2003
-----------------------------------	--------------------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No. EJ676053605US
PD-5670-01-MJA

Please type a plus sign (+) inside this box →

File
copy

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
in collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ORIGINALLY FILED

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/075,929
Filing Date	February 13, 2002
First Named Inventor	Leslie Magnus-Miller, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	5670-D1-01-CP

U.S. PATENT DOCUMENTS

~~RECEIVED~~

JUN 18 2002

Technology Center 2600

RECEIVED

JUN 27 2002

OFFICE OF PETITIONS

FOREIGN PATENT DOCUMENTS

Examiner
Signature

JAMES M. SPEAR

Date
Considered

05-20-2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)
Assumed (facing through 10/21/2008) GMD 2001-0001

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE
Collection of Information under Title 17, U.S.C., Section 1111

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Completeness Known

Application Number	10/075,929
Filing Date	February 13, 2002
First Named Inventor	Leslie Magnus-Miller, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	5670-D1-01-CFP

JUN 11 2002

+

COPY OF PAPERS
ORIGINALLY FILED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner
Signature

JAMES M. SPEAR

Date
Considered

05-20-2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.